다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of pharmaceutical investigation, v.53 no.1, 2023년, pp.119 - 152
Jeong, Seung-Hyun (College of Pharmacy, Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju, 61186 Republic of Korea) , Jang, Ji-Hun (College of Pharmacy, Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju, 61186 Republic of Korea) , Lee, Yong-Bok (College of Pharmacy, Chonnam National University, 77 Yongbong-ro, Buk-gu, Gwangju, 61186 Republic of Korea)
AI-Helper
BackgroundCranial nerve-related diseases such as brain tumors, Alzheimer’s disease, and epilepsy are serious diseases that continue to threaten human. Brain-related diseases are increasing worldwide, including in the United States and Korea, and these increases are closely related to the expos...
Abd Elgadir M Uddin MS Ferdosh S Adam A Chowdhury AJK Sarker MZI Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: a review J Food Drug Anal 2015 23 619 629 10.1016/j.jfda.2014.10.008 28911477
Abdou EM Kandil SM Miniawy HMFE Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion Int J Pharm 2017 529 667 677 10.1016/j.ijpharm.2017.07.030 28729175
Agarwal SK Kriel RL Brundage RC Ivaturi VD Cloyd JC A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers Epilepsy Res 2013 105 362 367 10.1016/j.eplepsyres.2013.02.018 23561287
Agrawal M Saraf S Saraf S Antimisiaris SG Chougule MB Shoyele SA Alexander A Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs J Control Release 2018 281 139 177 10.1016/j.jconrel.2018.05.011 29772289
Albayram MS Smith G Tufan F Tuna IS Bostancıklıoğlu M Zile M Albayram O Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes Nat Commun 2022 13 1 14 10.1038/s41467-021-27887-0 34983933
Alexander A Khan J Saraf S Saraf S Formulation and evaluation of chitosan-based long-acting injectable hydrogel for PEGylated melphalan conjugate J Pharm Pharmacol 2014 66 1240 1250 10.1111/jphp.12262 24824413
Aleya L Uddin MS Environmental pollutants and the risk of neurological disorders Environ Sci Pollut Res 2020 27 44657 44658 10.1007/s11356-020-11272-3
Al-Ghananeem AM Traboulsi AA Dittert LW Hussain AA Targeted brain delivery of 17β-estradiol via nasally administered water soluble prodrugs AAPS PharmSciTech 2002 3 40 47 10.1208/pt030105
Al-Salama ZT Scott LJ Sumatriptan nasal powder: a review in acute treatment of migraine Drugs 2016 76 1477 1484 10.1007/s40265-016-0641-9 27681528
Anderson BC Pandit NK Mallapragada SK Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels J Control Release 2001 70 157 167 10.1016/S0168-3659(00)00341-2 11166416
Ascough S Vlachantoni I Kalyan M Haijema B-J Wallin-Weber S Dijkstra-Tiekstra M Ahmed MS van Roosmalen M Grimaldi R Zhang Q Local and systemic immunity against Respiratory Syncytial virus induced by a novel intranasal vaccine. A randomized, double-blind, placebo-controlled clinical trial Am J Respir Crit Care Med 2019 200 481 492 10.1164/rccm.201810-1921OC 30753101
Astete CE Dolliver D Whaley M Khachatryan L Sabliov CM Antioxidant poly(lactic-co-glycolic) acid nanoparticles made with α-tocopherol–ascorbic acid surfactant ACS Nano 2011 5 9313 9325 10.1021/nn102845t 22017172
Bahadur S Pathak K Buffered nanoemulsion for nose to brain delivery of ziprasidone hydrochloride: preformulation and pharmacodynamic evaluation Curr Drug Deliv 2012 9 596 607 10.2174/156720112803529792 22788695
Bahadur S Pardhi DM Rautio J Rosenholm JM Pathak K Intranasal nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders Pharmaceutics 2020 12 1230 1256 10.3390/pharmaceutics12121230 33352959
Baldrick P The safety of chitosan as a pharmaceutical excipient Regul Toxicol Pharmacol 2010 56 290 299 10.1016/j.yrtph.2009.09.015 19788905
Banks WA Characteristics of compounds that cross the blood-brain barrier BMC Neurol 2009 9 1 5 10.1186/1471-2377-9-S1-S3 19126193
Bawarshi-Nassar RN Hussain AA Crooks PA Nasal absorption and metabolism of progesterone and 17 beta-estradiol in the rat Drug Metab Dispos 1989 17 248 254 2568904
Benedict C Brede S Schiöth HB Lehnert H Schultes B Born J Hallschmid M Intranasal insulin enhances postprandial thermogenesis and lowers postprandial serum insulin levels in healthy men Diabetes 2011 60 114 118 10.2337/db10-0329 20876713
Berkowitz R Bernstein D LaForce C Pedinoff A Rooklin A Damaraju C Mesarina-Wicki B Nolop K Onset of action of mometasone furoate nasal spray (NASONEX®) in seasonal allergic rhinitis Allergy 1999 54 64 69 10.1034/j.1398-9995.1999.00713.x 10195359
Bies C Lehr C-M Woodley JF Lectin-mediated drug targeting: history and applications Adv Drug Deliv Rev 2004 56 425 435 10.1016/j.addr.2003.10.030 14969751
Boche M Pokharkar V Quetiapine nanoemulsion for intranasal drug delivery: evaluation of brain-targeting efficiency AAPS PharmSciTech 2017 18 686 696 10.1208/s12249-016-0552-9 27207184
Borchard G Lueβen HL de Boer AG Verhoef JC Lehr C-M Junginger HE The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro J Control Release 1996 39 131 138 10.1016/0168-3659(95)00146-8
Brunnlieb C Münte TF Krämer U Tempelmann C Heldmann M Vasopressin modulates neural responses during human reactive aggression Soc Neurosci 2013 8 148 164 10.1080/17470919.2013.763654 23360100
Ceña V Játiva P Nanoparticle crossing of blood–brain barrier: a road to new therapeutic approaches to central nervous system diseases Nanomedicine 2018 13 1513 1516 10.2217/nnm-2018-0139 29998779
Chatterjee B Gorain B Mohananaidu K Sengupta P Mandal UK Choudhury H Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges Int J Pharm 2019 565 258 268 10.1016/j.ijpharm.2019.05.032 31095983
Chen X Zhi F Jia X Zhang X Ambardekar R Meng Z Paradkar AR Hu Y Yang Y Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel J Pharm Pharmacol 2013 65 807 816 10.1111/jphp.12043 23647674
Cho H-J Balakrishnan P Park E-K Song K-W Hong S-S Jang T-Y Kim K-S Chung S-J Shim C-K Kim D-D Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride J Pharm Sci 2011 100 681 691 10.1002/jps.22314 20803575
Craft S Baker LD Montine TJ Minoshima S Watson GS Claxton A Arbuckle M Callaghan M Tsai E Plymate SR Green PS Leverenz J Cross D Gerton B Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial Arch Neurol 2012 69 29 38 10.1001/archneurol.2011.233 21911655
Craft S Raman R Chow TW Rafii MS Sun C-K Rissman RA Donohue MC Brewer JB Jenkins C Harless K Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial JAMA Neurol 2020 77 1099 1109 10.1001/jamaneurol.2020.1840 32568367
Daly EJ Singh JB Fedgchin M Cooper K Lim P Shelton RC Thase ME Winokur A Van Nueten L Manji H Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial JAMA Psychiat 2018 75 139 148 10.1001/jamapsychiatry.2017.3739
Di Mauro TM (2008) Intranasally administering curcumin prodrugs to the brain to treat Alzheimer’s disease, Google Patents.
Diaz J Intranasal ketamine preinduction of paediatric outpatients Paediatr Anaesth 1997 7 273 278 10.1046/j.1460-9592.1997.d01-93.x 9243683
Elnaggar YS Etman SM Abdelmonsif DA Abdallah OY Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer’s disease: optimization, biological efficacy, and potential toxicity J Pharm Sci 2015 104 3544 3556 10.1002/jps.24557
Emirzeoglu M Sahin B Celebi M Uzun A Bilgic S Tontus H Estimation of nasal cavity and conchae volumes by stereological method Folia Morphol 2012 71 105 108
Eskandari S Varshosaz J Minaiyan M Tabbakhian M Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model Int J Nanomed 2011 6 363 371
Espinoza LC Silva-Abreu M Clares B Rodríguez-Lagunas MJ Halbaut L Cañas M-A Calpena AC Formulation strategies to improve nose-to-brain delivery of donepezil Pharmaceutics 2019 11 64 79 10.3390/pharmaceutics11020064 30717264
FDA (2009) Information for Patanase nasal spray. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021861s002lbl.pdf . Accessed 17 June 2022
FDA (2012) Information for Synarel nasal solution. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019886s030lbl.pdf . Accessed 17 June 2022
FDA (2015) Information for Narcan nasal spray. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf . Accessed 17 June 2022
FDA (2017a) Information for Miacalcin nasal spray. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017a/020313s036lbl.pdf . Accessed 17 June 2022
FDA (2017b) Information for Noctiva nasal spray. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017b/201656lbl.pdf . Accessed 17 June 2022
FDA (2019) Information for Baqsimi nasal powder. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf . Accessed 17 June 2022
FDA (2021a) Information for FluMist quadrivalent. https://www.fda.gov/vaccines-blood-biologics/vaccines/flumist-quadrivalent . Accessed 17 June 2022
FDA (2021b) Information for Trudhesa nasal spray. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021b/213436s000lbl.pdf . Accessed 17 June 2022
Feigin VL Nichols E Alam T Bannick MS Beghi E Blake N Culpepper WJ Dorsey ER Elbaz A Ellenbogen RG Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol 2019 18 459 480 10.1016/S1474-4422(18)30499-X 30879893
Feigin VL Vos T Alahdab F Amit AML Bärnighausen TW Beghi E Beheshti M Chavan PP Criqui MH Desai R Burden of neurological disorders across the US from 1990–2017: a global burden of disease study JAMA Neurol 2021 78 165 176 10.1001/jamaneurol.2020.4152 33136137
Feng C Zhang C Shao X Liu Q Qian Y Feng L Chen J Zha Y Zhang Q Jiang X Enhancement of nose-to-brain delivery of basic fibroblast growth factor for improving rat memory impairments induced by co-injection of β-amyloid and ibotenic acid into the bilateral hippocampus Int J Pharm 2012 423 226 234 10.1016/j.ijpharm.2011.12.008 22193058
Foo MY Cheng Y-S Su W-C Donovan MD The influence of spray properties on intranasal deposition J Aerosol Med 2007 20 495 508 10.1089/jam.2007.0638 18158721
Francis GJ Martinez JA Liu WQ Xu K Ayer A Fine J Tuor UI Glazner G Hanson LR Frey WH Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy Brain 2008 131 3311 10.1093/brain/awn288 19015157
Frey TM Florin TA Caruso M Zhang N Zhang Y Mittiga MR Effect of intranasal ketamine vs fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial JAMA Pediatr 2019 173 140 146 10.1001/jamapediatrics.2018.4582 30592476
Gabor F Bogner E Weissenboeck A Wirth M The lectin–cell interaction and its implications to intestinal lectin-mediated drug delivery Adv Drug Deliv Rev 2004 56 459 480 10.1016/j.addr.2003.10.015 14969753
Gänger S Schindowski K Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa Pharmaceutics 2018 10 116 143 10.3390/pharmaceutics10030116 30081536
Gao X Wu B Zhang Q Chen J Zhu J Zhang W Rong Z Chen H Jiang X Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration J Control Release 2007 121 156 167 10.1016/j.jconrel.2007.05.026 17628165
Gizurarson S Gudbrandsson FK Jonsson H Bechgaard E Intranasal administration of diazepam aiming at the treatment of acute seizures: clinical trials in healthy volunteers Biol Pharm Bull 1999 22 425 427 10.1248/bpb.22.425 10328567
Guastella AJ Howard AL Dadds MR Mitchell P Carson DS A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder Psychoneuroendocrinology 2009 34 917 923 10.1016/j.psyneuen.2009.01.005 19246160
Haider MF Khan S Gaba B Alam T Baboota S Ali J Ali A Optimization of rivastigmine nanoemulsion for enhanced brain delivery: in-vivo and toxicity evaluation J Mol Liq 2018 255 384 396 10.1016/j.molliq.2018.01.123
Hanafy AS Farid RM ElGamal SS Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer’s disease management: preparation and detection in rat brain Drug Dev Ind Pharm 2015 41 2055 2068 10.3109/03639045.2015.1062897 26133084
Hanafy AS Farid RM Helmy MW ElGamal SS Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer’s disease management Drug Deliv 2016 23 3111 3122 10.3109/10717544.2016.1153748 26942549
Hardy J Lee S Wilson C Intranasal drug delivery by spray and drops J Pharm Pharmacol 1985 37 294 297 10.1111/j.2042-7158.1985.tb05069.x 2862235
Hogan RE Gidal BE Koplowitz B Koplowitz LP Lowenthal RE Carrazana E Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers Epilepsia 2020 61 455 464 10.1111/epi.16449 32065672
Horvát S Fehér A Wolburg H Sipos P Veszelka S Tóth A Kis L Kurunczi A Balogh G Kürti L Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue Eur J Pharm Biopharm 2009 72 252 259 10.1016/j.ejpb.2008.10.009 19007885
Hosseini Jahromi S Hosseini Valami S Adeli N Yazdi Z Comparison of the effects of intranasal midazolam versus different doses of intranasal ketamine on reducing preoperative pediatric anxiety: a prospective randomized clinical trial J Anesth 2012 26 878 882 10.1007/s00540-012-1422-6 22688444
Hsu M Sandor M Fabry Z Current concepts on communication between the central nervous system and peripheral immunity via lymphatics: what roles do lymphatics play in brain and spinal cord disease pathogenesis? Biol Futura 2021 72 45 60 10.1007/s42977-021-00066-4
Huang Y Donovan M Microsphere transport pathways in the rabbit nasal mucosa Int J Pharm Adv 1996 1 298 309
Hussain MA Aungst BJ Shefter E Prodrugs for improved oral β-estradiol bioavailability Pharm Res 1988 5 44 47 10.1023/A:1015863412137 3244608
Illum L Watts P Fisher A Hinchcliffe M Norbury H Jabbal-Gill I Nankervis R Davis S Intranasal delivery of morphine J Pharmacol Exp Ther 2002 301 391 400 10.1124/jpet.301.1.391 11907197
Iqbal R Ahmed S Jain GK Vohora D Design and development of letrozole nanoemulsion: a comparative evaluation of brain targeted nanoemulsion with free letrozole against status epilepticus and neurodegeneration in mice Int J Pharm 2019 565 20 32 10.1016/j.ijpharm.2019.04.076 31051232
Jackson EM Herbst-Kralovetz MM Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine PLoS ONE 2012 7 e41529 10.1371/journal.pone.0041529 22855691
Jalloh M Esketamine (Spravato) for treatment-resistant depression Am Fam Physician 2020 101 339 340 32163257
James SL Abate D Abate KH Abay SM Abbafati C Abbasi N Abbastabar H Abd-Allah F Abdela J Abdelalim A Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 Lancet 2018 392 1789 1858 10.1016/S0140-6736(18)32279-7 30496104
Jang J-H Jeong S-H Lee Y-B Preparation and in vitro/in vivo characterization of polymeric nanoparticles containing methotrexate to improve lymphatic delivery Int J Mol Sci 2019 20 3312 3335 10.3390/ijms20133312 31284483
Jang J-H Jeong S-H Lee Y-B Enhanced lymphatic delivery of methotrexate using W/O/W nanoemulsion: in vitro characterization and pharmacokinetic study Pharmaceutics 2020 12 978 995 10.3390/pharmaceutics12100978 33081266
Javadzadeh M Sheibani K Hashemieh M Saneifard H Intranasal midazolam compared with intravenous diazepam in patients suffering from acute seizure: a randomized clinical trial Iran J Pediatr 2012 22 1 8 23056852
Jeong S-H Jang J-H Cho H-Y Lee Y-B Soft-and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery Arch Pharm Res 2018 41 797 814 10.1007/s12272-018-1060-0 30074202
Jeong S-H Jang J-H Lee Y-B Oral delivery of topotecan in polymeric nanoparticles: lymphatic distribution and pharmacokinetics J Control Release 2021 335 86 102 10.1016/j.jconrel.2021.05.017 34015399
Jeong S-H Jang J-H Lee Y-B Pharmacokinetic comparison between methotrexate-loaded nanoparticles and nanoemulsions as hard- and soft-type nanoformulations: a population pharmacokinetic modeling approach Pharmaceutics 2021 13 1050 1075 10.3390/pharmaceutics13071050 34371740
Jiang Y Liu C Zhai W Zhuang N Han T Ding Z The optimization design of lactoferrin loaded hupa nanoemulsion for targeted drug transport via intranasal route Int J Nanomed 2019 14 9217 9234 10.2147/IJN.S214657
Jogani VV Shah PJ Mishra P Mishra AK Misra AR Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting Alzheimer Dis Assoc Disord 2008 22 116 124 10.1097/WAD.0b013e318157205b 18525282
Khallaf RA Aboud HM Sayed OM Surface modified niosomes of olanzapine for brain targeting via nasal route; preparation, optimization, and in vivo evaluation J Liposome Res 2020 30 163 173 10.1080/08982104.2019.1610435 31039651
Kim TW Chung H Kwon IC Sung HC Jeong SY In vivo gene transfer to the mouse nasal cavity mucosa using a stable cationic lipid emulsion Mol Cells 2000 10 142 147 10.1007/s10059-000-0142-1 10850654
Klein EJ Brown JC Kobayashi A Osincup D Seidel K A randomized clinical trial comparing oral, aerosolized intranasal, and aerosolized buccal midazolam Ann Emerg Med 2011 58 323 329 10.1016/j.annemergmed.2011.05.016 21689865
Kratzer TB Siegel RL Miller KD Sung H Islami F Jemal A Progress against cancer mortality 50 years after passage of the National Cancer Act JAMA Oncol 2022 8 156 159 10.1001/jamaoncol.2021.5668 34762103
Kumar M Misra A Babbar AK Mishra AK Mishra P Pathak K Intranasal nanoemulsion based brain targeting drug delivery system of risperidone Int J Pharm 2008 358 285 291 10.1016/j.ijpharm.2008.03.029 18455333
Kumar S Ali J Baboota S Design Expert® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease Nanotechnology 2016 27 435101 10.1088/0957-4484/27/43/435101 27655136
Li J Wu H Hong J Xu X Yang H Wu B Wang Y Zhu J Lai R Jiang X Odorranalectin is a small peptide lectin with potential for drug delivery and targeting PLoS ONE 2008 3 e2381 10.1371/journal.pone.0002381 18584053
Li W Zhou Y Zhao N Hao B Wang X Kong P Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes Environ Toxicol Pharmacol 2012 34 272 279 10.1016/j.etap.2012.04.012 22613079
Lipton RB Munjal S Brand-Schieber E Rapoport AM DFN-02 (sumatriptan 10 mg with a permeation enhancer) nasal spray vs placebo in the acute treatment of migraine: a double-blind, placebo-controlled study Headache 2018 58 676 687 10.1111/head.13309 29878341
Lochhead JJ Thorne RG Intranasal delivery of biologics to the central nervous system Adv Drug Deliv Rev 2012 64 614 628 10.1016/j.addr.2011.11.002 22119441
Mahajan HS Mahajan MS Nerkar PP Agrawal A Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting Drug Deliv 2014 21 148 154 10.3109/10717544.2013.838014 24128122
Mathure D Madan JR Gujar KN Tupsamundre A Ranpise HA Dua K Formulation and evaluation of niosomal in situ nasal gel of a serotonin receptor agonist, buspirone hydrochloride for the brain delivery via intranasal route Pharm Nanotechnol 2018 6 69 78 10.2174/2211738506666180130105919 29380709
Mayer AV Wermter A-K Stroth S Alter P Haberhausen M Stehr T Paulus FM Krach S Kamp-Becker I Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism Sci Rep 2021 11 1 13 10.1038/s41598-021-94407-x 33414495
Md S Ali M Ali R Bhatnagar A Baboota S Ali J Donepezil nanosuspension intended for nose to brain targeting: in vitro and in vivo safety evaluation Int J Biol Macromol 2014 67 418 425 10.1016/j.ijbiomac.2014.03.022 24705169
Meng Q Wang A Hua H Jiang Y Wang Y Mu H Wu Z Sun K Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease Int J Nanomed 2018 13 705 718 10.2147/IJN.S151474
Mercadante S Prestia G Adile C Casuccio A Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen J Pain 2014 15 602 607 10.1016/j.jpain.2014.02.002 24561001
Migliore MM Vyas TK Campbell RB Amiji MM Waszczak BL Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations J Pharm Sci 2010 99 1745 1761 10.1002/jps.21939 19774660
Mischley LK Leverenz JB Lau RC Polissar NL Neradilek MB Samii A Standish LJ A randomized, double-blind phase I/II a study of intranasal glutathione in Parkinson’s disease Mov Disord 2015 30 1696 1701 10.1002/mds.26351 26230671
Moore T Croy S Mallapragada S Pandit N Experimental investigation and mathematical modeling of Pluronic® F127 gel dissolution: drug release in stirred systems J Control Release 2000 67 191 202 10.1016/S0168-3659(00)00215-7 10825553
Munjal S Brand-Schieber E Allenby K Spierings EL Cady RK Rapoport AM A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine J Headache Pain 2017 18 1 8 10.1186/s10194-017-0740-3 28058534
Nasr M Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery Drug Deliv 2016 23 1444 1452 10.3109/10717544.2015.1092619 26401600
NBTS (2022) Quick brain tumor facts. https://brain.tumor.org/brain-tumor-information/brain-tumor-facts/
Nonaka N Farr SA Kageyama H Shioda S Banks WA Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins J Pharmacol Exp Ther 2008 325 513 519 10.1124/jpet.107.132381 18270319
Owens DE III Peppas NA Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int J Pharm 2006 307 93 102 10.1016/j.ijpharm.2005.10.010 16303268
Pal S Incidence and prevalence of major neurologic disorders 2018 New York Jobson Publishing LLC 24 24
Pandey YR Kumar S Gupta BK Ali J Baboota S Intranasal delivery of paroxetine nanoemulsion via the olfactory region for the management of depression: formulation, behavioural and biochemical estimation Nanotechnology 2015 27 025102 10.1088/0957-4484/27/2/025102 26629830
Pandey V Gadeval A Asati S Jain P Jain N Roy RK Tekade M Soni V Tekade RK Formulation strategies for nose-to-brain delivery of therapeutic molecules Drug delivery systems 2020 Amsterdam Elsevier 291 332
Pardeshi CV Belgamwar VS Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting Expert Opin Drug Deliv 2013 10 957 972 10.1517/17425247.2013.790887 23586809
Pardridge WM Blood–brain barrier and delivery of protein and gene therapeutics to brain Front Aging Neurosci 2020 11 373 399 10.3389/fnagi.2019.00373 31998120
Pastor L Frutos M Grana L Ramos D Gallego-Huidobro J Calvo A Histochemical study of glycoconjugates in the nasal mucosa of the rat and guinea pig Histochem J 1992 24 727 736 10.1007/BF01460825 1428998
Pathak R Prasad Dash R Misra M Nivsarkar M Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route Acta Pharm Sin B 2014 4 151 160 10.1016/j.apsb.2014.02.002 26579378
Pentón-Arias E Aguilar-Rubido JC Cuban prophylactic and therapeutic vaccines for controlling hepatitis B MED Rev 2021 23 21 29
Pesic M Schippers F Saunders R Webster L Donsbach M Stoehr T Pharmacokinetics and pharmacodynamics of intranasal remimazolam—a randomized controlled clinical trial Eur J Clin Pharmacol 2020 76 1505 1516 10.1007/s00228-020-02984-z 32886178
Pietrowsky R Strüben C Mölle M Fehm HL Born J Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans Biol Psychiatry 1996 39 332 340 10.1016/0006-3223(95)00180-8 8704064
Pietrowsky R Thiemann A Kern W Fehm HL Born J A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin Psychoneuroendocrinology 1996 21 559 572 10.1016/S0306-4530(96)00012-1 8983091
Prince M Comas-Herrera A Knapp M Guerchet M Karagiannidou M Improving healthcare for people living with dementia: coverage, quality and costs now and in the future World Alzheimer Rep 2016 2016 140
Qian S Wong YC Zuo Z Development, characterization and application of in situ gel systems for intranasal delivery of tacrine Int J Pharm 2014 468 272 282 10.1016/j.ijpharm.2014.04.015 24709220
Rejman J Oberle V Zuhorn IS Hoekstra D Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis Biochem J 2004 377 159 169 10.1042/bj20031253 14505488
Rezaeian A Effect of intranasal insulin on olfactory recovery in patients with hyposmia: a randomized clinical trial Otolaryngol Head Neck Surg 2018 158 1134 1139 10.1177/0194599818764624 29557250
Rilling JK DeMarco AC Hackett PD Thompson R Ditzen B Patel R Pagnoni G Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men Psychoneuroendocrinology 2012 37 447 461 10.1016/j.psyneuen.2011.07.013 21840129
Rinaldi F Seguella L Gigli S Hanieh P Del Favero E Cantù L Pesce M Sarnelli G Marianecci C Esposito G inPentasomes: an innovative nose-to-brain pentamidine delivery blunts MPTP parkinsonism in mice J Control Release 2019 294 17 26 10.1016/j.jconrel.2018.12.007 30529726
Rogol A Tkachenko N Bryson N Natesto™, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men Andrology 2016 4 46 54 10.1111/andr.12137 26695758
Rohrer J Lupo N Bernkop-Schnürch A Advanced formulations for intranasal delivery of biologics Int J Pharm 2018 553 8 20 10.1016/j.ijpharm.2018.10.029 30316796
Sabzghabaee AM Eizadi-Mood N Yaraghi A Zandifar S Naloxone therapy in opioid overdose patients: intranasal or intravenous? A randomized clinical trial Arch Med Sci 2014 10 309 314 10.5114/aoms.2014.42584 24904666
Salem HF Kharshoum RM Abou-Taleb HA Naguib DM Brain targeting of resveratrol through intranasal lipid vesicles labelled with gold nanoparticles: in vivo evaluation and bioaccumulation investigation using computed tomography and histopathological examination J Drug Target 2019 27 1127 1134 10.1080/1061186X.2019.1608553 31094230
Schmidt H Kern W Giese R Hallschmid M Enders A Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial J Med Genet 2009 46 217 222 10.1136/jmg.2008.062141 18948358
Seju U Kumar A Sawant K Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies Acta Biomater 2011 7 4169 4176 10.1016/j.actbio.2011.07.025 21839863
Selvaraj K Gowthamarajan K Karri VVSR Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting Artif Cells Nanomed Biotechnol 2018 46 2088 2095 29282995
Shah B Khunt D Misra M Padh H Application of Box–Behnken design for optimization and development of quetiapine fumarate loaded chitosan nanoparticles for brain delivery via intranasal route* Int J Biol Macromol 2016 89 206 218 10.1016/j.ijbiomac.2016.04.076 27130654
Shimonovich S Gigi R Shapira A Sarig-Meth T Nadav D Rozenek M West D Halpern P Intranasal ketamine for acute traumatic pain in the Emergency Department: a prospective, randomized clinical trial of efficacy and safety BMC Emerg Med 2016 16 1 9 10.1186/s12873-016-0107-0 26728878
Ship JA Chávez EM Special senses: disorders of taste and smell Oral Med 2002 52 277
Sood S Jain K Gowthamarajan K Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment Colloids Surf B 2014 113 330 337 10.1016/j.colsurfb.2013.09.030
Suico JG Hövelmann U Zhang S Shen T Bergman B Sherr J Zijlstra E Frier BM Plum-Mörschel L Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: a randomised, open-label, crossover study Diabetes Ther 2020 11 1591 1603 10.1007/s13300-020-00845-7 32514794
Sun B-L Wang L-h Yang T Sun J-y Mao L-l Yang M-f Yuan H Colvin RA Yang X-y Lymphatic drainage system of the brain: a novel target for intervention of neurological diseases Prog Neurobiol 2018 163 118 143 10.1016/j.pneurobio.2017.08.007 28903061
Suzuki Y Kamigaki T Fujino Y Tominaga M Ku Y Kuroda Y Randomized clinical trial of preoperative intranasal mupirocin to reduce surgical-site infection after digestive surgery Br J Surg 2003 90 1072 1075 10.1002/bjs.4269 12945073
Thiebaud N Menetrier F Belloir C Minn A-L Neiers F Artur Y Le Bon A-M Heydel J-M Expression and differential localization of xenobiotic transporters in the rat olfactory neuro-epithelium Neurosci Lett 2011 505 180 185 10.1016/j.neulet.2011.10.018 22015764
Tsze DS Ieni M Fenster DB Babineau J Kriger J Levin B Dayan PS Optimal volume of administration of intranasal midazolam in children: a randomized clinical trial Ann Emerg Med 2017 69 600 609 10.1016/j.annemergmed.2016.08.450 27823876
Ugwoke MI Verbeke N Kinget R The biopharmaceutical aspects of nasal mucoadhesive drug delivery J Pharm Pharmacol 2001 53 3 22 10.1211/0022357011775145 11206189
Veronese FM Mero A The impact of PEGylation on biological therapies BioDrugs 2008 22 315 329 10.2165/00063030-200822050-00004 18778113
Vyas TK Babbar A Sharma R Singh S Misra A Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting J Pharm Sci 2006 95 570 580 10.1002/jps.20480 16419051
Wani TU Raza SN Khan NA Nanoparticle opsonization: forces involved and protection by long chain polymers Polym Bull 2020 77 3865 3889 10.1007/s00289-019-02924-7
Wanneveich M Moisan F Jacqmin-Gadda H Elbaz A Joly P Projections of prevalence, lifetime risk, and life expectancy of Parkinson’s disease (2010–2030) in France Mov Disord 2018 33 1449 1455 10.1002/mds.27447 30145805
Wermeling DP A response to the opioid overdose epidemic: naloxone nasal spray Drug Deliv Transl Res 2013 3 63 74 10.1007/s13346-012-0092-0 23734342
Whitcroft K Merkonidis C Cuevas M Haehner A Philpott C Hummel T Intranasal sodium citrate solution improves olfaction in post-viral hyposmia Rhinology 2016 54 368 374 10.4193/Rhino16.054 27316224
WHO (2022) Epilepsy. https://www.who.int/news-room/fact-sheets/detail/epilepsy
Wolff SC Brubaker K Navratil T Fulcher E Lankford J Boyer J Anticholinergic effects of antihistamine drugs used in the clinic J Allergy Clin Immunol 2007 119 S153 10.1016/j.jaci.2006.11.535
Wu H Li J Zhang Q Yan X Guo L Gao X Qiu M Jiang X Lai R Chen H A novel small odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-β25–35-treated rats following intranasal administration Eur J Pharm Biopharm 2012 80 368 378 10.1016/j.ejpb.2011.10.012 22061263
Wu S Huang J Zhang Z Wu J Zhang J Hu H Zhu T Zhang J Luo L Fan P Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial Lancet Infect Dis 2021 21 1654 1664 10.1016/S1473-3099(21)00396-0 34324836
Yadav S Gattacceca F Panicucci R Amiji MM Comparative biodistribution and pharmacokinetic analysis of cyclosporine-A in the brain upon intranasal or intravenous administration in an oil-in-water nanoemulsion formulation Mol Pharm 2015 12 1523 1533 10.1021/mp5008376 25785492
Yamasue H Okada T Munesue T Kuroda M Fujioka T Uno Y Matsumoto K Kuwabara H Mori D Okamoto Y Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial Mol Psychiatry 2020 25 1849 1858 10.1038/s41380-018-0097-2 29955161
Yang T Hussain A Bai S Khalil IA Harashima H Ahsan F Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin J Control Release 2006 115 289 297 10.1016/j.jconrel.2006.08.015 17023085
Yang Z-Z Zhang Y-Q Wang Z-Z Wu K Lou J-N Qi X-R Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration Int J Pharm 2013 452 344 354 10.1016/j.ijpharm.2013.05.009 23680731
Yates R Nairn K Dixon R Seaber E Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers J Clin Pharmacol 2002 42 1237 1243 10.1177/009127002762491325 12412822
Zhang JC Zhang F Intranasal delivery of calcitonin gene-related peptide reduces cerebral vasospasm in rats Front Biosci 2010 2 1502 1513
Zhang X Bai X Zhang Q Wang X Lu L The safety and efficacy of intranasal dexmedetomidine during electrochemotherapy for facial vascular malformation: a double-blind, randomized clinical trial J Oral Maxillofac Surg 2013 71 1835 1842 10.1016/j.joms.2013.06.202 23945510
Zhang C Chen J Feng C Shao X Liu Q Zhang Q Pang Z Jiang X Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer's disease Int J Pharm 2014 461 192 202 10.1016/j.ijpharm.2013.11.049 24300213
Zhao Y Yue P Tao T Qh CHEN Drug brain distribution following intranasal administration of Huperzine a in situ gel in rats 3 Acta Pharmacol Sin 2007 28 273 278 10.1111/j.1745-7254.2007.00486.x 17241531
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.